Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer

Chesner, Lisa N ; Polesso, Fanny ; Graff, Julie N ; Hawley, Jessica E ; Smith, Alexis K ; Lundberg, Arian ; Das, Rajdeep ; Shenoy, Tanushree ; Sjöström, Martin LU and Zhao, Faming , et al. (2025) In Cancer Discovery 15(3). p.481-494
Abstract

Immunotherapy options for immune cold tumors, like prostate cancer, are limited. We show that AR downregulates MHCI expression/antigen presentation and that AR inhibition improves T-cell responses and tumor control. This suggests that treatments combining AR inhibitors and checkpoint blockade may improve tumor immune surveillance and antitumor immunity in patients.

Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Male, Humans, Prostatic Neoplasms/immunology, Androgen Receptor Antagonists/pharmacology, Animals, Mice, Receptors, Androgen/metabolism, Histocompatibility Antigens Class I/metabolism, Cell Line, Tumor
in
Cancer Discovery
volume
15
issue
3
pages
481 - 494
publisher
American Association for Cancer Research Inc.
external identifiers
  • scopus:86000610260
  • pmid:39652470
ISSN
2159-8274
DOI
10.1158/2159-8290.CD-24-0559
language
English
LU publication?
yes
additional info
©2024 The Authors; Published by the American Association for Cancer Research.
id
bc5818ac-65a9-48f2-814a-4f02d75dd15c
date added to LUP
2026-02-09 14:13:40
date last changed
2026-02-10 04:02:22
@article{bc5818ac-65a9-48f2-814a-4f02d75dd15c,
  abstract     = {{<p>Immunotherapy options for immune cold tumors, like prostate cancer, are limited. We show that AR downregulates MHCI expression/antigen presentation and that AR inhibition improves T-cell responses and tumor control. This suggests that treatments combining AR inhibitors and checkpoint blockade may improve tumor immune surveillance and antitumor immunity in patients.</p>}},
  author       = {{Chesner, Lisa N and Polesso, Fanny and Graff, Julie N and Hawley, Jessica E and Smith, Alexis K and Lundberg, Arian and Das, Rajdeep and Shenoy, Tanushree and Sjöström, Martin and Zhao, Faming and Hu, Ya-Mei and Linder, Simon and Chen, William S and Hawkins, Reed M and Shrestha, Raunak and Zhu, Xiaolin and Foye, Adam and Li, Haolong and Kim, Lisa M and Bhalla, Megha and O'loughlin, Thomas and Kuzuoglu-Ozturk, Duygu and Hua, Junjie T and Badura, Michelle L and Wilkinson, Scott and Trostel, Shana Y and Bergman, Andries M and Ruggero, Davide and Drake, Charles G and Sowalsky, Adam G and Fong, Lawrence and Cooperberg, Matthew R and Zwart, Wilbert and Guan, Xiangnan and Ashworth, Alan and Xia, Zheng and Quigley, David A and Gilbert, Luke A and Feng, Felix Y and Moran, Amy E}},
  issn         = {{2159-8274}},
  keywords     = {{Male; Humans; Prostatic Neoplasms/immunology; Androgen Receptor Antagonists/pharmacology; Animals; Mice; Receptors, Androgen/metabolism; Histocompatibility Antigens Class I/metabolism; Cell Line, Tumor}},
  language     = {{eng}},
  month        = {{03}},
  number       = {{3}},
  pages        = {{481--494}},
  publisher    = {{American Association for Cancer Research Inc.}},
  series       = {{Cancer Discovery}},
  title        = {{Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer}},
  url          = {{http://dx.doi.org/10.1158/2159-8290.CD-24-0559}},
  doi          = {{10.1158/2159-8290.CD-24-0559}},
  volume       = {{15}},
  year         = {{2025}},
}